Global /United States /Healthcare /Biotechnology /AVTE

Aerovate Therapeutics, Inc.

AVTE

• NASDAQ: AVTE • Delayed

93.80USD 3K%

As of 14 June 2026, Aerovate Therapeutics, Inc. has a market cap of $77.68M USD, ranking #27361 globally and #4154 in the United States. It ranks #2458 in the Healthcare sector, and #474 in the Biotechnology industry.

Global Rank

27361

Country Rank

4154

Sector Rank

2458

Industry Rank

474

Key Stats

Market Cap

$77.68MUSD

Enterprise Value

$1.78MUSD

EBITDA (TTM)

-$53.11MUSD

Net Income (TTM)

-$48.96MUSD

PB Ratio

1.0

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Timothy Noyes open_in_new

Employees

Founded

2018

IPO

30 Jun 2021

Website

aerovatetx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
3K%	3K%	4K%	4K%	4K%	3K%	331%	569%	-90%

News

AVTE Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	AVTE Aerovate Therapeutics Inc ISIN: US0080641071 Shares Out.: Shares Outstanding: 28.985M¹ Shares Float: 21.127M² TV: TradingView: NASDAQ: AVTE SA: Stock Analysis: NASDAQ: AVTE YF: Yahoo Finance: AVTE GF: Google Finance: NASDAQ: AVTE NQ: NASDAQ: AVTE BA: Barron's: AVTE MS: Morningstar: XNAS: AVTE	93.80 USD	TV: TradingView: NASDAQ: AVTE SA: Stock Analysis: NASDAQ: AVTE YF: Yahoo Finance: AVTE GF: Google Finance: NASDAQ: AVTE NQ: NASDAQ: AVTE BA: Barron's: AVTE MS: Morningstar: XNAS: AVTE

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 235K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 206K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 35K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 34K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 32K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 23K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 61K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 58K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 54K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 54K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 36K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 33K%	-	Germany

chevron_leftBack